Patents by Inventor Noriyoshi Yamamoto
Noriyoshi Yamamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9029572Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.Type: GrantFiled: June 13, 2014Date of Patent: May 12, 2015Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
-
Publication number: 20140371459Abstract: Provided is a method for producing a compound represented by formula (7) or a salt thereof: the method comprising the steps of: removing a R1 group and a R2 group from a compound represented by formula (5) or a salt thereof: and reacting the compound (in which R1 and R2 in formula (5) are hydrogen atoms) obtained in the removing step or a salt thereof with a compound represented by formula (d): or a salt thereof in the presence of a base. The method is a method for producing a 1,2-dihydroquinoline derivative having glucocorticoid receptor binding activity or a salt thereof. This method does not require a purification step by column chromatography and is suitable for industrial production.Type: ApplicationFiled: January 21, 2013Publication date: December 18, 2014Applicants: SANTEN PHARMACEUTICAL CO., LTD., KYOWA HAKKO BIO CO., LTD.Inventors: Noriyoshi Yamamoto, Atsushi Ohno, Kazuhiro Kudou, Masakazu Ban, Takashi Mimura, Takashi Ohtani
-
Publication number: 20140296540Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventors: Kazuhiro KUDOU, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
-
Patent number: 8802869Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.Type: GrantFiled: February 8, 2012Date of Patent: August 12, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
-
Publication number: 20130310576Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.Type: ApplicationFiled: February 8, 2012Publication date: November 21, 2013Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
-
Patent number: 7923461Abstract: A compound having the following formula wherein A is —O—; B is alkylene or alkenylene optionally containing —O—, —S—, —(NR7)—, —CO— or —N?; R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl is unsubstituted or substituted by halogen, cycloalkyl, aryl, adamantyl or amino; R3 is a substituted or unsubstituted pyridine ring; R5 and R6 are hydrogen or alkyl; R7 is hydrogen or alkyl; X is O or S; and each hydrogen of the said amino is unsubstituted or substituted by alkyl, alkoxycarbonyl, cycloalkyloxycarbonyl, arylalkoxycarbonyl or halogenoalkyloxycarbonyl. The compound is a TNF-? production inhibitor that is useful for treating autoimmune diseases such as rheumatoid arthritis.Type: GrantFiled: September 23, 2009Date of Patent: April 12, 2011Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Publication number: 20100016380Abstract: A compound having the following formula wherein A is —O—; B is alkylene or alkenylene optionally containing —O—, —S—, —(NR7)—, —CO— or —N?; R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl is unsubstituted or substituted by halogen, cycloalkyl, aryl, adamantyl or amino; R3 is a substituted or unsubstituted pyridine ring; R5 and R6 are hydrogen or alkyl; R7 is hydrogen or alkyl; X is O or S; and each hydrogen of the said amino is unsubstituted or substituted by alkyl, alkoxycarbonyl, cycloalkyloxycarbonyl, arylalkoxycarbonyl or halogenoalkyloxycarbonyl. The compound is a TNF-? production inhibitor that is useful for treating autoimmune diseases such as rheumatoid arthritis.Type: ApplicationFiled: September 23, 2009Publication date: January 21, 2010Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Patent number: 7491739Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein “A” is —(NR4)—, —(CR5R6)— or —O—, “B” is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and “X” is oxygen or sulfer respectively.Type: GrantFiled: June 7, 2006Date of Patent: February 17, 2009Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Publication number: 20080182881Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein A is —(NR4)—, —(CR5R6)— or —O—, B is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfer respectively.Type: ApplicationFiled: August 15, 2007Publication date: July 31, 2008Applicant: SANTEN PHARMACEUTICAL, CO., LTD.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Patent number: 7345064Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein A is —(NR4)—, —(CR5R6)— or —O—, B is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfer respectively.Type: GrantFiled: June 22, 2006Date of Patent: March 18, 2008Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Publication number: 20060241155Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein A is —(NR4)—, —(CR5R6)— or —O—, B is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfer respectively.Type: ApplicationFiled: June 22, 2006Publication date: October 26, 2006Applicant: SANTEN PHARMACEUTICAL, CO., LTD.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Publication number: 20060229342Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein “A” is —(NR4)—, —(CR5R6)— or —O—, “B” is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and “X” is oxygen or sulfer respectively.Type: ApplicationFiled: June 7, 2006Publication date: October 12, 2006Applicant: SANTEN PHARMACEUTICAL, CO., LTD.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Patent number: 7098226Abstract: A purpose of the present invention is to provide TNF-? production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-? production inhibitory activities, wherein “A” is —(NR4)—, —(CR5R6)— or —O—, “B” is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R3 is aryl or an unsaturated heterocycle, and “X” is oxygen or sulfer respectively.Type: GrantFiled: May 31, 2001Date of Patent: August 29, 2006Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto, Hiroyuki Inoue
-
Publication number: 20030032623Abstract: A purpose of the present invention is to provide TNF-&agr; production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis.Type: ApplicationFiled: June 21, 2002Publication date: February 13, 2003Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto
-
Patent number: 6267757Abstract: The invention is directed to an intracorporeal device for myocardial revascularization of a patient's heart tissue by at least one burst of RF energy over an interval of about 1 to about 500 msec, preferably about 30 to about 130 msec. The intracorporeal device has an elongated insulated, electrical conducting shaft with an uninsulated distal tip which is configured to emit RF energy. The uninsulated distal tip has a diameter of about 0.025 to about 0.2 inch, preferably about 0.04 to about 0.08 inch and a length of about 0.1 to about 5 mm, preferably about 1.5 to about 3.5 mm.Type: GrantFiled: October 2, 1997Date of Patent: July 31, 2001Assignee: Eclipse Surgical Technologies, Inc.Inventors: Michael Aita, Daniel Burkhoff, Noriyoshi Yamamoto, Miriam H. Taimisto, Kenneth P. Aron, Christopher J. Danek
-
Patent number: 5968980Abstract: The present invention relates to compounds represented by the formula [I] and salts thereof, wherein R.sup.1 and R.sup.5 each represents carboxyl, phosphonic or a derivative thereof; R.sup.2 represents hydrogen, lower alkyl, (substituted) phenyl lower alkyl, lower alkoxy or (substituted) phenyl lower alkoxy; R.sup.3 represents lower alkyl or (substituted) phenyl lower alkyl; and R.sup.4 represents a group represented by the formula [XI], [XII] or [XIII]. The compounds of the present invention have endopeptidase 24.11 inhibitory activity and are useful for treating cardiovascular diseases such as heart failure and hypertension, renal diseases such as renal failure, gastroenteric disorders such as diarrhea and hyperchlorhydria, endocrine and metabolic diseases such as obesity, and autoimmune diseases such as rheumatic disease, and for mitigating myosalgia, migraine, etc.Type: GrantFiled: June 3, 1997Date of Patent: October 19, 1999Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Yoichi Kawashima, Ken-ichi Fujimura, Hiroshi Suhara, Noriyoshi Yamamoto, Hiromi Matsumoto, Nobuaki Miyawaki, Yuko Fujita
-
Patent number: 5865309Abstract: A dual-chambered container includes a chamber which contains, for example, a dry drug and a chamber which contains, for example, a medical liquid. The chambers are defined in first and second bags, with each bag having a weak seal formed in a side thereof. The bags are formed separately and then joined to one another so that the weak seals therein are positioned so that a passageway is formed between the bags when the weak seals are forcibly broken. The chambers can be sterilized independently of each other and, consequently, the container can be manufactured in a manner which minimizes the amount of labor required.Type: GrantFiled: October 24, 1997Date of Patent: February 2, 1999Assignee: Nissho CorporationInventors: Hitoshi Futagawa, Noriyoshi Yamamoto
-
Patent number: 5706937Abstract: A flexible and dual-chambered container includes a first frontal sheet fusion bonded to a first rear sheet to define a first chamber for containing, for example, a medical liquid. The first frontal sheet is a flexible and transparent sheet for intercepting water, moisture, and oxygen gas. The first rear sheet is a flexible composite sheet composed of aluminum foil and a water-absorbing stratum. A second frontal sheet is fusion bonded to a second rear sheet to define a second chamber for containing, for example, a medical liquid. The second frontal and rear sheets are joined to the first frontal and rear sheets so that the first and second chambers are isolated by a breakable or weak seal. An opaque and flexible cover sheet composed of aluminum foil is removably disposed on the first frontal sheet. When the weak seal is broken by manually compressing the second chamber, the first and second chambers are brought into liquid communication.Type: GrantFiled: March 18, 1996Date of Patent: January 13, 1998Assignee: Nissho CorporationInventors: Hitoshi Futagawa, Noriyoshi Yamamoto, Masanobu Iwasa
-
Patent number: 5692960Abstract: The homokinetic joint has an inner ring and and an outer ring formed with axial track grooves so as to be opposite to each other, balls received in the track grooves, a cage mounted between the inner and outer rings and having pockets accommodating the respective balls, whereby torque is transmitted between the inner and outer rings through the balls so that the inner and outer rings will rotate at the same speed. The distance between said track grooves formed in the inner ring and those formed in the outer ring is determined so that the balls are fitted in the grooves between the ring and the inner ring with a predetermined interference, while leaving an axial clearance between the pockets of the cage and the balls. Thus, the balls can roll smoothly with little play in the direction of rotation.Type: GrantFiled: May 31, 1995Date of Patent: December 2, 1997Assignee: NTN CorporationInventors: Tatsuro Sugiyama, Noriyoshi Yamamoto, Hisaaki Kura
-
Patent number: 4525622Abstract: The heat generating member in a ceramic glow plug is a coil embedded in the ceramic. The coil is wound to have a coil angle, i.e. an angle formed between the coil and a line parallel to the coil axis, of no more than 60.degree.. The ceramic may be a non-oxide ceramic, nitride ceramic, SiC ceramic, or the like.Type: GrantFiled: January 30, 1984Date of Patent: June 25, 1985Assignees: Isuzu Motor, Ltd., Kyoto Ceramic Co., Ltd.Inventors: Hideo Kawamura, Nobukazu Sagawa, Noriyoshi Yamamoto